Little Green Pharma
Financials
Estimates*
AUD | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
---|---|---|---|---|---|---|---|
Revenues | 2.2m | 7.0m | - | 19.6m | 25.6m | 29.8m | 35.5m |
% growth | - | 218 % | - | - | 31 % | 16 % | 19 % |
EBITDA | (8.8m) | 25.4m | - | (4.6m) | (4.5m) | <1m | 3.2m |
% EBITDA margin | (399 %) | 362 % | - | (24 %) | (17 %) | 1 % | 9 % |
Profit | (9.3m) | 24.6m | - | (9.2m) | (8.2m) | (3.0m) | <1m |
% profit margin | (423 %) | 351 % | - | (47 %) | (32 %) | (10 %) | - |
EV / revenue | 17.0x | 18.7x | - | 2.7x | 1.6x | 1.0x | 0.8x |
EV / EBITDA | -4.3x | 5.2x | - | -11.4x | -9.4x | 143.8x | 8.9x |
R&D budget | 1.0m | 1.8m | - | 6.6m | 6.3m | - | - |
R&D % of revenue | 46 % | 25 % | - | 34 % | 25 % | - | - |
Date | Investors | Amount | Round |
---|---|---|---|
* | N/A | $2.5m | Early VC |
N/A | N/A | IPO | |
AUD50.0k | Grant | ||
N/A | AUD300k | Grant | |
N/A | AUD5.0m | Post IPO Equity | |
AUD27.2m | Post IPO Equity | ||
AUD50.0k | Grant | ||
* | N/A | AUD5.0m | Post IPO Equity |
Total Funding | €2.5m |
Recent News about Little Green Pharma
EditLittle Green Pharma is a pioneering company in the Australian medical cannabis market, specializing in the production and distribution of high-quality, pharmaceutical-grade cannabis products. The company serves a diverse range of clients including healthcare professionals and patients seeking effective medicinal cannabis treatments. Operating primarily within the Australian market, Little Green Pharma leverages its locally grown cannabis to ensure quality and efficacy. The business model revolves around manufacturing and distributing cannabis oil preparations, which are sold through a network of healthcare providers and directly to patients. Revenue is generated through the sale of these medicinal products, as well as through educational resources and support services offered via their Medical Portal for healthcare professionals. The company is listed on the Australian Securities Exchange (ASX) under the ticker LGP, and has achieved significant milestones including obtaining a Good Manufacturing Practices (GMP) licence from the Therapeutic Goods Administration (TGA).
Keywords: medical cannabis, pharmaceutical-grade, Australian market, cannabis oil, healthcare professionals, patients, GMP licence, ASX LGP, locally grown, high-quality.